Noeparast, A., Giron, P., De Brakeleer, S., Eggermont, C., De Ridder, U., Teugels, E., & De Grève, J. (2018). Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. Oncotarget.

Noeparast, Amir, Philippe Giron, Sylvia De Brakeleer, Carolien Eggermont, Ulrike De Ridder, Erik Teugels, and Jacques De Grève. "Type II RAF Inhibitor Causes Superior ERK Pathway Suppression Compared to Type I RAF Inhibitor in Cells Expressing Different BRAF Mutant Types Recurrently Found in Lung Cancer." Oncotarget 2018.

Noeparast, Amir, et al. "Type II RAF Inhibitor Causes Superior ERK Pathway Suppression Compared to Type I RAF Inhibitor in Cells Expressing Different BRAF Mutant Types Recurrently Found in Lung Cancer." Oncotarget 2018.